Literature DB >> 16828513

Management of congenital nonpigmented iris cyst.

Christopher C Shen1, Peter A Netland, Matthew W Wilson, William R Morris.   

Abstract

PURPOSE: Previously reported clinical outcomes after treatment of congenital iris cysts have been poor, complicated by cyst recurrence and vision loss. Our purpose was to evaluate the outcomes of surgical excision and microdiathermy of congenital iris cysts.
DESIGN: Interventional retrospective case series.
METHODS: Four patients (3 children, 1 adult) were treated for a congenital iris cyst based on history and clinical presentation. After cyst excision with caution to avoid cyst rupture, the base of the cyst was treated with microdiathermy. MAIN OUTCOME MEASURE: Presence or absence of a residual cyst after surgical intervention.
RESULTS: In all 4 patients, histopathological findings confirmed the diagnosis of a congenital iris cyst. Follow-up periods ranged from 1.4 to 6.2 years (mean +/- standard deviation, 4+/-2). Vision loss did not occur in any of the treated eyes. No cyst recurrence was noted after initial surgical treatment.
CONCLUSION: A modern microsurgical technique with adjunctive use of microdiathermy provides improved outcomes in the surgical management of congenital iris cysts. We believe that microdiathermy applied to the base of the cyst removes residual epithelial tissue that accounted for the recurrences documented in previous reports.

Entities:  

Mesh:

Year:  2006        PMID: 16828513     DOI: 10.1016/j.ophtha.2006.04.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  2 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Ab externo laser photocoagulation for the treatment of spontaneous iris stromal cyst.

Authors:  Atchareeya Wiwatwongwana; Nimitr Ittipunkul; Damrong Wiwatwongwana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-13       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.